Paclitaxel Albumin-Bound — Drug Intelligence | 83 EU Trials

Filter these 83 trials by condition, phase, country and more.

Open in Search →

83 Registered trials

33 Recruiting

42 Completed trials

49 Sponsors

21 Countries

Phase III

Phase II

Phase III: 39 Phase II/III: 6 Phase II: 23 Phase I/II: 7 Phase IV: 2 Phase I (FiH): 6

Oversight events:

2 serious breaches 10 temporary halts 3 urgent safety measures 2 unexpected events 1 corrective measure across 10 trials

View oversight register →

Indications tested

Non-small cell lung cancer metastatic 7 Triple negative breast cancer 4 Breast cancer 4 Hormone receptor positive breast cancer 3 Breast cancer metastatic 3 Fallopian tube cancer 2 Hormone receptor positive HER2 negative breast cancer 2 Non-small cell lung cancer 2 Ovarian cancer 2 Peritoneal neoplasm 2 Haematological malignancy 1 Invasive breast carcinoma 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 12 Gilead Sciences Inc. 6 F. Hoffmann-La Roche AG 5 AstraZeneca AB 4 Bristol-Myers Squibb Services Unlimited Company 4 Genmab A/S 3 Unicancer 3 Corcept Therapeutics Inc. 2 Incyte Corp. 2 IRCCS Istituto Nazionale Tumori Fondazione Pascale 2 Region Hovedstaden 2 Aalborg University Hospital 1

All trials

83 total

HARMONi-3 Not authorised

2023-504989-37-00 Phase III 7 countries Summit Therapeutics Sub Inc.
A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III … Pending

2024-519031-42-00 Phase III 1 country Associazione Italiana Per Lo Studio Del Pancreas
A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36 Pending

2025-522084-15-00 Phase II/III 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale
Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer Pending

2025-522431-34-00 Phase II 1 country Region Hovedstaden
A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS … Pending

2025-523432-39-01 Phase I/II 6 countries Verastem Inc.
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ… Pending

2025-524095-27-00 Phase II 2 countries Gilead Sciences Inc.
Trial to study the safety and pharmacokinetics of ODM-212 combined with existing cancer treatments Pending

2025-524620-22-00 Phase I/II 4 countries Orion Corporation
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic P… Pending

2025-525009-18-00 Phase III 11 countries Incyte Corp.
A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants wit… Recruiting

2025-523204-68-00 Phase II 3 countries Jazz Pharmaceuticals Ireland Limited
ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting

2025-521884-12-00 Phase III 8 countries BioNTech SE
LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and… Recruiting

2023-508995-12-01 Phase II 4 countries Novartis Pharma AG
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Phase III 5 countries Unicancer
HER2DX-guided diagnostic treatment For patients with HER2-positive early-stage breast cancer Recruiting

2025-521040-37-00 Phase III 4 countries Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques Augus…
A Study of Navlimetostat (BMS-986504) in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy… Recruiting

2025-521511-40-00 Phase II/III 15 countries Bristol-Myers Squibb Services Unlimited Company
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Rec… Recruiting

2025-520582-51-00 Phase III 7 countries Merck Sharp & Dohme LLC
SUPRAME - ACTengine® IMA203 vs. investigator’s choice of treatment in previously treated, unresectable or metastatic cutaneous melanoma Recruiting

2024-517062-42-00 Phase III 3 countries Immatics US Inc.
Randomized Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Ade… Recruiting

2024-513317-12-00 Phase III 9 countries Arcus Biosciences Inc.
Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re… Recruiting

2023-504918-29-00 Phase III 16 countries Merck Sharp & Dohme LLC
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or… Recruiting

2025-523461-17-01 Phase III 8 countries Pfizer Inc.
A clinical study of V940 in people with non-small cell lung cancer (V940-013) Recruiting

2025-520902-37-00 Phase II 4 countries Merck Sharp & Dohme LLC
Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced… Recruiting

2024-519871-24-00 Phase II/III 10 countries Bristol-Myers Squibb Services Unlimited Company
A clinical study of sacituzumab tirumotecan with or without pembrolizumab in people with breast cancer (MK-2870-011) Recruiting

2024-516834-36-00 Phase III 13 countries Merck Sharp & Dohme LLC
RR001, a cell-based gene therapy administered in combination with chemotherapy for the treatment of patients with locally advanced pancreati… Recruiting

2024-516019-26-00 Phase I (FiH) 1 country Eir Biotherapies S.r.l.
An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens … Recruiting

2024-517432-21-00 Phase II 6 countries Corcept Therapeutics Inc.

Showing 1–24 of 83 trials

← All drugs A–Z